Pathologically decreased expression of miR-193a contributes to metastasis by targeting WT1-E-cadherin axis in non-small cell lung cancers

[1]  E. Morii,et al.  Deficiency in WT1-targeting microRNA-125a leads to myeloid malignancies and urogenital abnormalities , 2016, Oncogene.

[2]  Wei Jiang,et al.  Prognostic value of high FoxC2 expression in resectable non-small cell lung cancer, alone or in combination with E-cadherin expression , 2016, BMC Cancer.

[3]  W. Hiddemann,et al.  A 4‐gene expression score associated with high levels of Wilms Tumor‐1 (WT1) expression is an adverse prognostic factor in acute myeloid leukaemia , 2015, British journal of haematology.

[4]  Xiaoying Guan,et al.  MicroRNA-29b attenuates non-small cell lung cancer metastasis by targeting matrix metalloproteinase 2 and PTEN , 2015, Journal of experimental & clinical cancer research : CR.

[5]  A. Zaravinos.  The Regulatory Role of MicroRNAs in EMT and Cancer , 2015, Journal of oncology.

[6]  Xianghuo He,et al.  Quantitative Proteomic Analysis of the Metastasis-Inhibitory Mechanism of miR-193a-3p in Non-Small Cell Lung Cancer , 2015, Cellular Physiology and Biochemistry.

[7]  J. Gamble,et al.  miR‐181a mediates TGF‐β‐induced hepatocyte EMT and is dysregulated in cirrhosis and hepatocellular cancer , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[8]  Hongwei Liang,et al.  miR-193a-3p Functions as a Tumor Suppressor in Lung Cancer by Down-regulating ERBB4* , 2014, The Journal of Biological Chemistry.

[9]  Alfredo Hidalgo-Miranda,et al.  miRNA biogenesis: Biological impact in the development of cancer , 2014, Cancer biology & therapy.

[10]  Cui-ping Xu,et al.  The new concepts on overcoming drug resistance in lung cancer , 2014, Drug design, development and therapy.

[11]  A. Puisieux,et al.  Oncogenic roles of EMT-inducing transcription factors , 2014, Nature Cell Biology.

[12]  B. Liu,et al.  MiR-132 Suppresses the Migration and Invasion of Lung Cancer Cells via Targeting the EMT Regulator ZEB2 , 2014, PloS one.

[13]  Bob van de Water,et al.  β1 Integrin Inhibition Elicits a Prometastatic Switch Through the TGFβ–miR-200–ZEB Network in E-Cadherin–Positive Triple-Negative Breast Cancer , 2014, Science Signaling.

[14]  D. Rao,et al.  miRNA dysregulation in cancer: towards a mechanistic understanding , 2014, Front. Genet..

[15]  Lang Li,et al.  Exploring a structural protein-drug interactome for new therapeutics in lung cancer. , 2014, Molecular bioSystems.

[16]  Tao Yu,et al.  MicroRNA-193a-3p and -5p suppress the metastasis of human non-small-cell lung cancer by downregulating the ERBB4/PIK3R3/mTOR/S6K2 signaling pathway , 2014, Oncogene.

[17]  A. Gemma,et al.  MiR-134/487b/655 Cluster Regulates TGF-β–Induced Epithelial–Mesenchymal Transition and Drug Resistance to Gefitinib by Targeting MAGI2 in Lung Adenocarcinoma Cells , 2013, Molecular Cancer Therapeutics.

[18]  W. Gallagher,et al.  miRNA dysregulation in breast cancer. , 2013, Cancer research.

[19]  X. Chen,et al.  Wilms’ tumour suppressor gene 1 (WT1) is involved in the carcinogenesis of Lung cancer through interaction with PI3K/Akt pathway , 2013, Cancer Cell International.

[20]  Yijiang Chen,et al.  WT1 Promotes Invasion of NSCLC via Suppression of CDH1 , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  C. Croce,et al.  MicroRNA-31 Predicts the Presence of Lymph Node Metastases and Survival in Patients with Lung Adenocarcinoma , 2013, Clinical Cancer Research.

[22]  J. Xu,et al.  WT1 Promotes Cell Proliferation in Non-Small Cell Lung Cancer Cell Lines through Up-Regulating Cyclin D1 and p-pRb In Vitro and In Vivo , 2013, PloS one.

[23]  Xia Li,et al.  A novel miR-193a-5p-YY1-APC regulatory axis in human endometrioid endometrial adenocarcinoma , 2013, Oncogene.

[24]  B. Snaar-Jagalska,et al.  Snail and Slug, key regulators of TGF-β-induced EMT, are sufficient for the induction of single-cell invasion. , 2013, Biochemical and biophysical research communications.

[25]  Yih-Leong Chang,et al.  MicroRNA-135b promotes lung cancer metastasis by regulating multiple targets in the Hippo pathway and LZTS1 , 2013, Nature Communications.

[26]  J. Xiong,et al.  miR-149 Inhibits Non-Small-Cell Lung Cancer Cells EMT by Targeting FOXM1 , 2013, Biochemistry research international.

[27]  S. Kwak,et al.  Ionizing radiation-inducible microRNA miR-193a-3p induces apoptosis by directly targeting Mcl-1 , 2013, Apoptosis.

[28]  S. Tsujitani,et al.  Impact of dendritic cell vaccines pulsed with Wilms' tumour-1 peptide antigen on the survival of patients with advanced non-small cell lung cancers. , 2013, European journal of cancer.

[29]  M. Caligiuri,et al.  Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway. , 2013, Blood.

[30]  Y. Shang,et al.  Epigenetic control of epithelial-to-mesenchymal transition and cancer metastasis. , 2013, Experimental cell research.

[31]  M. Kitaichi,et al.  Low Wilms’ Tumor Gene Expression in Tumor Tissues Predicts Poor Prognosis in Patients with Non-Small-Cell Lung Cancer , 2012, Cancer investigation.

[32]  Christoph C Zielinski,et al.  Genome-Wide miRNA Expression Profiling Identifies miR-9-3 and miR-193a as Targets for DNA Methylation in Non–Small Cell Lung Cancers , 2012, Clinical Cancer Research.

[33]  Chong-yun Xing,et al.  miR-15a and miR-16-1 inhibit the proliferation of leukemic cells by down-regulating WT1 protein level , 2011, Journal of experimental & clinical cancer research : CR.

[34]  L. Gao,et al.  MicroRNA-193a represses c-kit expression and functions as a methylation-silenced tumor suppressor in acute myeloid leukemia , 2011, Oncogene.

[35]  P. Nelson,et al.  Metastatic progression of prostate cancer and e-cadherin regulation by zeb1 and SRC family kinases. , 2011, The American journal of pathology.

[36]  M. F. Shannon,et al.  An autocrine TGF-β/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition , 2011, Molecular biology of the cell.

[37]  S. Goodison,et al.  CD24, a promising biomarker in NSCLC. , 2010, Biomarkers in medicine.

[38]  M. Franco-Molina,et al.  WT1 gene silencing by aerosol delivery of PEI–RNAi complexes inhibits B16-F10 lung metastases growth , 2009, Cancer Gene Therapy.

[39]  Raghu Kalluri,et al.  The basics of epithelial-mesenchymal transition. , 2009, The Journal of clinical investigation.

[40]  S. Moriya,et al.  Expression of the WT1 gene -KTS domain isoforms suppresses the invasive ability of human lung squamous cell carcinoma cells. , 2008, International journal of oncology.

[41]  A. Yoshimura,et al.  E-cadherin expression and epidermal growth factor receptor mutation status predict outcome in non-small cell lung cancer patients treated with gefitinib. , 2008, Oncology reports.

[42]  Gema Moreno-Bueno,et al.  Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for Snail, Slug, and E47 factors in epithelial-mesenchymal transition. , 2006, Cancer research.

[43]  Anwar Hossain,et al.  N-terminally Truncated WT1 Protein with Oncogenic Properties Overexpressed in Leukemia* , 2006, Journal of Biological Chemistry.

[44]  A. Rajasekaran,et al.  Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. , 2006, Cancer research.

[45]  J. Thiery,et al.  Complex networks orchestrate epithelial–mesenchymal transitions , 2006, Nature Reviews Molecular Cell Biology.

[46]  Yan Shen,et al.  Formation of E-cadherin-mediated cell-cell adhesion activates AKT and mitogen activated protein kinase via phosphatidylinositol 3 kinase and ligand-independent activation of epidermal growth factor receptor in ovarian cancer cells. , 2005, Molecular endocrinology.

[47]  A. Chávez-Reyes,et al.  HER2/neu increases the expression of Wilms' Tumor 1 (WT1) protein to stimulate S-phase proliferation and inhibit apoptosis in breast cancer cells , 2005, Oncogene.

[48]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[49]  Long-Cheng Li,et al.  MethPrimer: designing primers for methylation PCRs , 2002, Bioinform..

[50]  S. Miyoshi,et al.  Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers , 2002, International journal of cancer.

[51]  J. Thiery.  Epithelial–mesenchymal transitions in tumour progression , 2002, Nature Reviews Cancer.

[52]  U. Maurer,et al.  Ribozyme-mediated cleavage of wt1 transcripts suppresses growth of leukemia cells. , 2001, Experimental hematology.

[53]  Keith R. Johnson,et al.  N-Cadherin Promotes Motility in Human Breast Cancer Cells Regardless of Their E-Cadherin Expression , 1999, The Journal of cell biology.

[54]  Y. Sonoda,et al.  Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. , 1997, Blood.

[55]  T. Kudoh,et al.  Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. , 1996, Blood.

[56]  D. Housman,et al.  Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus , 1990, Cell.

[57]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[58]  Helen Diller Family.  Targeting the TGFβ signalling pathway in disease , 2012 .

[59]  宮永 晃彦.  E-cadherin expression and epidermal growth factor receptor mutation status predict outcome in non-small cell lung cancer patients treated with gefitinib , 2008 .

[60]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[61]  W. Doerfler,et al.  DNA methylation and gene activity. , 1983, Annual review of biochemistry.